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Abstract
Background: We have shown that glucosamine (GlcN) or O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-
phenylcarbamate (PUGNAc) treatment augments O-linked-N-acetylglucosamine (O-GlcNAc) protein modification and
attenuates inflammatory mediator expression, leukocyte infiltration and neointima formation in balloon injured rat carotid
arteries and have identified the arterial smooth muscle cell (SMC) as the target cell in the injury response. NFkB signaling
has been shown to mediate the expression of inflammatory genes and neointima formation in injured arteries.
Phosphorylation of the p65 subunit of NFkB is required for the transcriptional activation of NFkB. This study tested the
hypothesis that GlcN or PUGNAc treatment protects vascular SMCs against tumor necrosis factor (TNF)-a induced
inflammatory stress by enhancing O-GlcNAcylation and inhibiting TNF-a induced phosphorylation of NFkB p65, thus
inhibiting NFkB signaling.
Methodology/Principal Findings: Quiescent rat aortic SMCs were pretreated with GlcN (5 mM), PUGNAc (10
24 M) or
vehicle and then stimulated with TNF-a (10 ng/ml). Both treatments inhibited TNF-a-induced expression of chemokines
[cytokine-induced neutrophil chemoattractant (CINC)-2b and monocyte chemotactic protein (MCP)-1] and adhesion
molecules [vascular cell adhesion molecule (VCAM)-1 and P-Selectin]. Both treatments inhibited TNF-a induced NFkB p65
activation and promoter activity, increased NFkB p65 O-GlcNAcylation and inhibited NFkB p65 phosphorylation at Serine
536, thus promoting IkBa binding to NFkB p65.
Conclusions: There is a reciprocal relationship between O-GlcNAcylation and phosphorylation of NFkB p65, such that
increased NFkB p65 O-GlcNAc modification inhibits TNF-a-Induced expression of inflammatory mediators through inhibition
of NFkB p65 signaling. These findings provide a mechanistic basis for our previous observations that GlcN and PUGNAc
treatments inhibit inflammation and remodeling induced by acute endoluminal arterial injury.
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Introduction
Inflammation plays an important role in the pathogenesis of
many forms of vascular disease, including responses to acute
vascular injury. Previous studies, including our own, have shown
that inflammatory mediator expression and leukocyte infiltration
in injured vessels contribute to vascular remodeling after
endoluminal injury [1–3]. Glucosamine (GlcN) is an amino sugar
that can stimulate O-GlcNAc modification (O-GlcNAcylation) of
proteins by increasing flux through the hexosamine biosynthesis
pathway, while O-(2-acetamido-2-deoxy-d-glucopyranosylidene)
amino-N-phenylcarbamate (PUGNAc) augments O-GlcNAc levels
by inhibiting O-GlcNAcase (OGA), which catalyzes the cleavage of
O-GlcNAc from modified proteins [4]. We have shown that both
GlcN and PUGNAc decrease expression of chemokines [cytokine-
induced neutrophil chemoattractant (CINC)-2b and monocyte
chemotactic protein (MCP)-1] and adhesion molecules [P-selectin
and vascular cell adhesion molecule (VCAM)-1], as well as
periadventitial infiltration of neutrophils and monocyte/macro-
phages in the setting of acute arterial injury in the rat, and that
chronic GlcN administration inhibits subsequent neointima
formation. These anti-inflammatory and vasoprotective effects
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24021are associated with increased levels of O-GlcNAc modified proteins
in injured blood vessels [5].
We have identified vascular smooth muscle cells (SMCs) as
critical ‘‘first responders’’ to acute vascular injury and have
developed the tumor necrosis factor (TNF)-a stimulated isolated
rat aortic smooth muscle cell (RASMC) as in in vitro model that
expresses the same pattern of inflammatory mediators as the
balloon injured artery in vivo [6]. Nuclear factor (NF) kB has been
shown to be activated in vascular injury [7,8], as well as in TNF-a
treated vascular SMCs, and NFkB activation is critical for the
expression of a variety of genes involved in vascular inflammation
[9–11]. Phosphorylation of the p65 subunit of NFkB is required
for the transcriptional activation of NFkB in a number of ways: by
stabilizing p65 protein, regulating DNA-binding activity, decreas-
ing the binding of p65 to IkBa and enhancing its transactivation
potential [12–18].
A reciprocal relationship between O-GlcNAcylation and
phosphorylation has been described for some proteins, including
estrogen receptor (ER)-b [19] and c-myc [20], suggesting that O-
GlcNAcylation and phosphorylation may modulate each other.
This study tested the hypothesis that increasing NFkB p65 O-
GlcNAc protein modification with GlcN and PUGNAc treatment
inhibits TNF-a-induced inflammatory responses in isolated
RASMCs by interfering with NFkB signaling.
Results
To determine whether GlcN and PUGNAc have anti-
inflammatory effects in RASMCs in vitro, we examined the
effects of GlcN and PUGNAc pretreatment on TNF-a stimulated
expression of pro-inflammatory chemokines (CINC-2b and MCP-
1) and adhesion molecules [vascular cell adhesion molecule
(VCAM)-1 and P-selectin] (Figure 1). Expression of the anti-
inflammatory mediator IL-10 was also examined as a negative
control. All mediators were expressed at low or undetectable levels
in unstimulated vehicle-treated RASMCs. Pretreatment with
GlcN or PUGNAc dose-dependently reduced mRNA levels of
the chemokines CINC-2b and MCP-1 and the adhesion molecule
VCAM-1 in TNF-a treated cells. Both GlcN and PUGNAc also
reduced mRNA level of P-selectin, but the PUGNAc effect was not
dose dependent over this range. Neither GlcN nor PUGNAc
affected TNF-a-induced IL-10 expression (Data not shown). GlcN
or PUGNAc alone had no effect on baseline expression of these
mediators. These results are consistent with our earlier in vivo
studies indicating that the VSMC is the target of the anti-
inflammatory and vasoprotective effects of GlcN and PUGNAc in
acutely injured arteries.
To determine whether the anti-inflammatory effect of GlcN and
PUGNAc was mediated through inhibition of TNF-a induced
activation of NFkB signaling, we assessed the effects of GlcN and
PUGNAc on NFkB p65 DNA binding activity in TNF-a treated
cells. TNF-a treatment significantly increased NFkB p65 DNA
binding activity compared to vehicle, and this effect was
attenuated by pretreatment with GlcN or PUGNAc (Figure 2A).
We also found that GlcN and PUGNAc inhibited TNF-a induced
NFkB promoter activity, assessed by luciferase activity in cells
transfected with the pNFkB-Luc luciferase reporter plasmid
(Figure 2B). Cells transfected with the empty control vector
showed no lucerfase activity under basal conditions or in response
to TNF-a (Data not shown). Taken together, these results indicate
that both GlcN and PUGNAc inhibit NFkB p65 activation in
TNF-a treated RASMCs.
We then tested the hypothesis that GlcN and PUGNAc
treatments result in increased O-GlcNAcylation of NFkB p65
and attenuated TNF-a-induced phosphorylation of NFkB p65,
thereby inhibiting NFkB activation and subsequent expression of
NFkB mediated inflammatory genes. To test whether NFkB p65
was O-GlcNAcylated, we carried out IP with the anti- O-GlcNAc
specific antibody 18B10.C7 (Millipore), followed by Western
blotting with an anti-p65 specific antibody (Abcam) (Figure 3A, B).
We found that GlcN and PUGNAc enhanced O-GlcNAcylated
p65 levels in cells that had been treated with vehicle or TNF-a;
however, TNF-a itself had no effect on p65 O-GlcNAc levels in
either vehicle treated or GlcN/PUGNAC treated cells. To
confirm the specificity of the anti-NFkB p65 antibody, samples
were pre-incubated with NFkB p65 blocking peptide and analyzed
by Western blot with anti-p65 antibody, and no signal was
detected (Figure S1, left panel); reprobing with anti-p65 antibody
revealed a strong 65KD band (Figure S1, right panel). Interest-
ingly, after probing the O-GlcNAc IP samples with anti-phos-p65
Ser 536 antibody, no signal was detectable (Figure 3A), while the
phos-p65 Ser 536 signal was detected in cell lysate before IP of the
same samples (Figure 3C), suggesting that O-GlcNAcylated p65
cannot be further phosphorylated in response to TNF-a treatment
in our cells.
Stimulus-induced phosphorylation of multiple amino acid
residues in the p65 subunit is required for transcriptional
activation of NFkB in various cell types [12–18,21–23]. TNF-a
has been shown to induce phosphorylation of NFkB p65 at several
serine (Ser) and threonine (Thr) residues, i.e. Thr 254, Ser 276 and
311 in the Rel homology domain (RHD) and Ser 529 and 536 in
the transactivation domain (TAD) in a variety of cell types.
Phosphorylation of these sites has been shown to stabilize p65
protein (Thr 254) [12], regulate DNA-binding activity (Ser 276)
[13], decrease the binding affinity of p65 to IkBa (Ser 536) [14]
and enhance transactivation potential (Ser 276, 311, 529 and 536)
[15–18,22,23]. We observed very low levels of phos-p65-Thr 254
and phos-p65-Ser 536, and moderate levels of phos-p65-Ser 311
and 529 in whole cell extracts from vehicle-treated RASMCs
(Figure 4); however, within 10 min of TNF-a treatment,
phosphorylation of p65 at Thr 254 and Ser 311 increased
significantly (by 20% and 2-fold, respectively) and then fell to basal
levels at 20 or 30 min (Figure 4). Levels of phos-p65-Ser 536
peaked within 10 min of TNF-a stimulation at ,10-fold baseline,
and remained elevated at 60 min (Figure 4). Phosphorylation of
p65 at Ser 529 was not altered in response to TNF-a treatment.
Phosphorylation of p65 at Ser 276 was not detected in either
vehicle or TNF-a treated cells (Data not shown).
Treatment with GlcN or PUGNAc alone had no effect on levels
of phos-p65 or total p65 compared to vehicle; however, both GlcN
and PUGNAc significantly attenuated TNF-a–induced Ser 536
phosphorylation of NFkB p65 by ,40% (Figure 5A) at 10 min of
treatment, but had no effect on TNF-a–induced phosphorylation
of NFkB p65 at Ser 311 or Thr 254. GlcN and PUGNAc also
inhibited the late phase of TNF-a-induced phosphorylation of p65
at Ser 536 (Figure 5B). These results suggest that GlcN and
PUGNAc primarily affect TNF-a induced phosphorylation of Ser
536 in RASMCs, raising the intriguing possibility that the key O-
GlcNAc modification sites responsible for the attenuation of NFkB
activation are in the vicinity of Ser 536, this means O-GlcNAc
modification sites are near Ser 536, not necessarily on Ser 536.
IkBa functions as a key negative regulator of NFkB activity,
acting in both the cytoplasm and nucleus. Thus, alterations in
IkBa could contribute to the inhibitory effects seen with GlcN and
PUGNAc treatment. However, GlcN and PUGNAc had no effect
on cytoplasmic degradation or resynthesis of IkBa in response to
TNF-a treatment in RASMCs (Figure 6A, B). We also tested the
possibility that increasing O-GlcNAcylation of p65 altered the
Anti-Inflammatory Effect of O-GlcNAcylated NFkBp65
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e24021Figure 1. Glucosamine and PUGNAc dose dependently inhibited inflammatory mediator expression in RASMCs. Expression of mRNA
for the pro-inflammatory chemokines [cytokine-induced neutrophil chemoattractant (CINC)-2b and monocyte chemotactic protein (MCP)-1] and
adhesion molecules [P-selectin and vascular cell adhesion molecule (VCAM)-1] were analyzed by real-time quantitative RT-PCR. Quiescent cells were
pretreated with GlcN (5–30 mM), PUGNAc (10
26–10
24 M) or vehicle for 1 hr, followed by TNF-a (10 ng/mL) for an additional 6 hrs. Data, expressed as
means6SEM, are normalized by 18S RNA. Data are standardized to the mean mRNA level of the TNF-a-treated RASMCs. n=5–6/group. *p,0.05 vs
respective vehicle-treated RASMCs; # p,0.05 vs respective TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0024021.g001
Anti-Inflammatory Effect of O-GlcNAcylated NFkBp65
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e24021basal nucleocytoplasmic shuttling properties of the NFkB-IkBa
complex, favoring nuclear export of NFkB. We observed no
detectable phos-p65-Ser 536 and very low levels of total p65 in
nuclear extracts from vehicle-treated cells (Figure 6C). In response
to TNF-a, phos-p65-Ser 536 and total p65 increased significantly
in this nuclear preparation. Pretreatment with GlcN or PUGNAc
significantly reduced the level of phos-p65-Ser 536 without
affecting total p65 in nuclear extracts of TNF-a treated cells.
Treatment with GlcN or PUGNAc alone had no effect on nuclear
levels of phos-p65-Ser 536 or total p65 compared to vehicle (Data
not shown). These results are consistent with the findings in the
whole cell lysates, indicating that GlcN and PUGNAc inhibit
phosphorylation of p65 at Ser 536, but not nuclear retension of
total p65.
To determine whether GlcN and PUGNAc enhanced the
interaction of IkBa and NFkB p65, RASMCs were treated with
TNF-a or vehicle for 1 hr and subjected to IP with anti-NFkB p65
followed by immunoblotting (IB) with anti-IkBa. The amount of
IkBa that coimmunoprecipitated with NFkB p65 decreased
dramatically in response to TNF-a; this was prevented by
pretreatment with GlcN or PUGNAc (Figure 6D). These results
suggest that GlcN and PUGNAc treatment enhanced the binding
of p65 to IkBa without altering protein levels of IkBa or NFkB
p65 in cells treated with TNF-a.
Discussion
This study provides the first demonstration that GlcN or
PUGNAc treatment inhibits TNF-a induced inflammatory
responses in SMCs by inhibiting NFkB p65 Ser 536 phosphor-
ylation, thus increasing sequestration of NFkB p65 by IkBa and
thereby attenuating activation of NFkB signalling. These provoc-
ative findings provide a mechanistic basis for our previous in vivo
observations that GlcN and PUGNAc decrease expression of
inflammatory mediators and infiltration of neutrophils and
monocytes into the periadventitial region of balloon injured rat
carotid arteries at a very early time point following endoluminal
injury, ultimately resulting in attenuation of neointima formation
and adverse vascular remodeling [5].
O-GlcNAcylation is an important regulatory mechanism that
modulates stress responses in the cardiovascular system [24–36].
For example, increasing O-GlcNAc levels in cardiac myocytes by
treatment with GlcN, PUGNAc or NAG-Bt and NAG-Ae, highly
selective O-GlcNAcase inhibitors, protects against ischemia-
reperfusion injury [24–29] and ischemic injury related to
myocardial infarction [30]. PUGNAc and GlcN treatments also
result in improved cardiac function and organ perfusion and
reduced circulating levels of IL-6 and TNF-a in association with
increased O-GlcNAc protein modification in the heart, liver, and
kidney of rats subjected to trauma-hemorrhage [31–33]. In this
model, attenuation of inflammatory mediator expression is related
to reduce NFkB activation [33]. These findings led us to postulate
that the anti-inflammatory effects of GlcN and PUGNAc
treatment that we had observed in the injured rat carotid artery
are related to O-GlcNAcylation of components of the NFkB
signaling pathway, resulting in reduced NFkB activation and an
attenuated vascular injury response. This hypothesis is consistent
with previous observations that activation of the NFkB pathway
plays an important role in the response to acute vascular injury in
animal models [7–8], and that blockade of NFkB by a variety of
means, including antisense p65, an NFkB decoy or by overex-
pression of IkBa, effectively inhibits inflammatory responses in
injured arteries [37–39].
Using the TNF-a treated RASMC, we have demonstrated that
increasing NFkB p65 O-GlcNAc modification with GlcN or
PUGNAc treatment inhibits NFkB activation and have delineated
the molecular mechanisms of this effect. We have shown that the
p65 subunit of NFkB is a target for O-GlcNAc modification in
GlcN or PUGNAc treated cells, and that this post translational
modification prevents its phosphorylation in response to TNF-a,
suggesting a reciprocal relationship between O-GlcNAcylation and
phosphorylation of NFkB p65 in RASMCs. We further showed
that, in cells pretreated with GlcN or PUGNAc, levels of O-
GlcNAcylated NFkB p65 were increased, and phosphorylation of
Ser-536 on NFkB p65 was significantly reduced in response to
TNF-a. Ser-536 is located in the COOH terminal TAD of p65
and its phosphorylation plays a key role in transcriptional
activation in response to stimuli such as TNF-a [18,23,40].
Figure 2. Glucosamine and PUGNAc inhibited NFkB activation in RASMCs. Quiescent cells were pretreated with GlcN (5 mM), PUGNAc
(10
24 M) or vehicle for 1 hr, followed by TNF-a (10 ng/mL) for an additional 1 hr. A: NFkB p65 DNA binding activity of nuclear extracts was measured
using the TransAM NFkB p65 transcription factor assay kit. Data, expressed as mean6SEM, are normalized to protein concentration. B. Cells were
transiently co-transfected with pNFkB-Luc, a luciferase reporter plasmid driven by NFkB response elements, and pRL-TK (control for transfection
efficiency) using Lipofectamine Plus Transfection Reagent (Invitrogen). Luciferase activities were measured using the dual luciferase assay system.
Data, expressed as mean6SEM, are normalized to protein concentration. (n)=number of samples. *p,0.05 vs. vehicle treated RASMCs; # p,0.05 vs.
TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0024021.g002
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phosphorylation of Ser-536 on p65 in nuclear extracts was also
reduced in cells pretreated with GlcN or PUGNAc. As a
consequence, overall NFkB p65 activation (determined by
TransAM NFkB p65 transcription factor assay and NFkB
luciferase reporter assay) and the p65 mediated expression of
inflammatory genes were significantly reduced.
Our demonstration of anti-inflammatory/vasoprotective effects
of GlcN in VSMCs and injured arteries is consistent with a large
body of literature showing that GlcN inhibits inflammation and
related pathological processes in noncardiovascular cells and
tissues. GlcN has been shown to suppress expression of the
proinflammatory mediators IL-6 and cyclooxygenase-2 in human
chondrocytes [41,42], to inhibit NFkB activation and IL-1b
bioactivity in rat chondrocytes [43], to downregulate TNF-a-
induced expression of ICAM in human retinal pigment epithelial
cells [44], to suppress neutrophil functions such as superoxide
generation, phagocytosis, granule enzyme release, and chemotaxis
[45], and to inhibit CD3-induced T cell activation [46]. Our
findings identifying NFkB p65 as a target for O-GlcNAc
modification and exploring the inhibitory effect of this post-
translational modification on NFkB activity provide a mechanistic
basis for the above observations.
Our finding of an apparent reciprocal relationship between O-
GlcNAcylation and phosphorylation of NFkB p65 in RASMCs is
consistent with a large body of evidence that O-GlcNAcylation is
akin to phosphorylation in that it occurs on serine and/or
threonine side chains of proteins, cycles rapidly upon cellular
activation, and may interfere with signaling pathways that are
mediated by phosphorylation [47]. O-GlcNAc and phosphate can
either competitively occupy a single site or proximal sites, or
noncompetitively occupy different sites on a substrate. Some
proteins such as p53 and murine estrogen receptor b are
reciprocally modified by O-GlcNAc and phosphate, and this
reciprocal relationship has been shown to be functionally
significant [19,20,48].
Our data demonstrate that increasing NFkB p65 O-GlcNAc
modification with GlcN or PUGNAc treatment prevents TNF-a-
induced phosphorylation of p65 at Ser 536, but not phosphory-
lation of p65 at Thr 254 and Ser 311, indicating that the specific
amino acid residues of NFkB p65 that can be O-GlcNAcylated in
GlcN or PUGNAc treated RASMCs are in the vicinity of Ser 536.
These results contrast with previous observations of increased
NFkB activity in association with increased O-GlcNAc modifica-
tion of Thr 352 in NFkB p65 in RASMCs under hyperglycemic
conditions [49,50]. In our study, O-GlcNAc modification of NFkB
p65 was a direct result of GlcN or PUGNAc treatment without the
confounding effect of high glucose, which can lead to oxidative
stress and advanced glycation end-product accumulation, as in
diabetic models [51]. Further, the finding of different sites of
phosphorylation/O-GlcNAc modification (Ser 536 in our study,
Thr 352 in the previous study) may account for differential effects
on NFkB activity and downstream inflammatory events.
We are aware that due to the lack of selective antibody for O-
GlcNAc p65, in the IP experiments we performed, an O-GlcNAc
modified protein that is bound to p65, rather than O-GlcNAc p65
per se might account for our results. Accordingly, our results need
to be confirmed by other approaches in the future. Another
limitation of the current study is the lack of specificity of the
pharmacologic agents used to elicit increases in protein O-
GlcNAcylation in our cells. We are aware that in addition to
increasing O-GlcNAc levels, GlcN also increases UDP-GlcNAc,
which is used for multiple N-glycosylation reactions that are
involved in protein synthesis. Glucosamine-6-phosphate could
potentially be metabolized to fructose-6-phosphate, thereby
increasing glycolytic flux. Thus, the anti-inflammatory effect seen
here with GlcN treatment could potentially be mediated via a
number of other pathways. PUGNAc is a potent competitive
inhibitor of OGA, but also inhibits other glycoside hydrolases such
as the lysosomal b-hexosaminidases and b-N-acetylglucosamini-
dases [52]. However, data from our group and others have shown
that enhancing O-GlcNAc modification of proteins using PUG-
NAc, NAG-Bt or NAG-Ae has anti-inflammatory and cardiovas-
cular protective effects in a range of in vitro and in vivo models
[24–36]. Further, it has been shown that overexpression of O-
GlcNAc transferase (OGT) or knockdown of OGA has same effect
as PUGNAc in reducing hypoxia-mediated oxidative stress and
Ca
2+ overload in cardiomyocytes [34,35], while overexpression of
Figure 3. Glucosamine and PUGNAc enhanced NFkB p65 O-
GlcNAcylation in RASMCs. Quiescent cells were pretreated with
GlcN (5 mM), PUGNAc (10
24 M) or vehicle for 1 hr, followed by TNF-a
(10 ng/mL) for an additional 1 hr. A. O-GlcNAc immunoprecipitates (IP)
obtained from cellular extracts were analyzed by Western blot for p65
and phos-p65-Ser 536. Cell lysates for IP were probed with GADPH for
input loading. B. The band intensity was measured and the ratio of O-
GlcNAc modified p65 (O-GlcNAc-p65) to the corresponding b-actin was
calculated. Data, expressed as means6SEM, are O-GlcNAc-p65/b-actin
ratios standardized to the mean ratio of the vehicle-treated RASMCs
shown in bar graph. (n)=number of samples. *p,0.05 vs. vehicle
treated RASMCs. C. Representative Western blots of phos-p65-Ser 536 in
cell lysate before IP. Blots was reprobed with antibody against b-actin
for input loading.
doi:10.1371/journal.pone.0024021.g003
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activation of NFkB and production of intercellular adhesion
molecule-1 and TNF-a in this cell type [33]. Together, this
evidence strongly supports the interpretation that the anti-
inflammatory effects of GlcN and PUGNAc seen in the current
study are indeed mediated via increased O-GlcNAc levels.
Methods
To assess the effect of GlcN and PUGNAc on the TNF-a-
induced inflammatory mediator expression, quiescent RASMCs
were pretreated with GlcN (5–30 mM), PUGNAc (10
26–10
24 M)
or vehicle and then stimulated with TNF-a (10 ng/ml) for 6 hrs.
Inflammatory mediator mRNA expression was assessed by real-
time RT-PCR as previously described [2,5,6]. To assess the effect
of GlcN and PUGNAc on the TNF-a-induced NFkB signaling
pathway, quiescent RASMCs were pretreated with GlcN (5 mM),
PUGNAc (10
24 M) or vehicle and then stimulated with TNF-a
(10 ng/ml) for 5, 10, 20, 30, 60 mins or 24 hrs, as described in
Results and Figure Legends. Overall NFkB p65 activation was
determined by TransAM NFkB p65 transcription factor assay and
NFkB luciferase reporter assay. NFkB signaling pathway mole-
cules, including IkBa,N F kB p65 and phosphorylated NFkB p65
(phos-p65) at different amino acid residues (Threonine 254, Serine
276, 311,468, 529 and 536) were measured by Western blot.
Binding of IkBa to NFkB p65 and O-GlcNAc modified NFkB p65
was assessed using immunoprecipitation (IP), followed by Western
blot.
Cell culture
Primary cultures of RASMCs were derived from 10-week-old
female Sprague-Dawley rats (Charles River), as previously
described [6]. All protocols were approved by the Institutional
Animal Care and Use Committee of the University of Alabama
Figure 4. TNF-a phosphorylated NFkB p65 time-dependently at Serine (Ser) and Threonine (Thr) residues in RASMCs. Quiescent cells
were treated with TNF-a (10 ng/mL) for the periods indicated. A: Representative Western blots of phosphorylated (phos-) p65 in TNF-a-treated
RASMCs with antibody against phos-Thr 254, phos-Ser 311, phos-Ser 529 and phos-Ser 536. Blots were reprobed with antibody against total p65 and
b-actin. Data, expressed as mean6SEM, are phos-p65/b-actin ratios as shown in line graphs. n=3/group. *p,0.05 vs. vehicle treated RASMCs.
doi:10.1371/journal.pone.0024021.g004
Anti-Inflammatory Effect of O-GlcNAcylated NFkBp65
PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e24021at Birmingham and were consistent with the Public Health
Service Policy on Humane Care and Use of Laboratory Animals
(Office of Laboratory Animal Welfare, August 2002) and the
Guide for the Care and Use of Laboratory Animals published by
National Institutes of Health (NIH Publication No. 96-01,
revised in 2002). The animal protocol number is 100908574.
Cells were cultured in complete medium containing phenol red–
free DMEM (Gibco) supplemented with 10% (vol/vol) FBS,
4 mmol/L L-glutamine, 100 U/mL penicillin, and 100 mg/ml
streptomycin. RASMCs were used within 5 passages and were
identified as RASMCs by their characteristic morphology and
positive immunostaining for a-smooth muscle actin (a-SMA,
clone 1A4, DAKO). RASMCs were pre-treated with GlcN
(5 mM), PUGNAc (10
24 M) or vehicle for 1 hr, then incubated
with TNF-a (10 ng/mL) for various time periods from 1 to
24 hrs.
Figure 5. Glucosamine and PUGNAc inhibited phosphorylation of NFkB p65 at Serine 536 in RASMCs. Quiescent cells were pretreated
with GlcN (5 mM), PUGNAc (10
24 M) or vehicle for 1 hr, followed by TNF-a (10 ng/mL) for an additional 10 min (A) or 1 hr (B). A: Representative
Western blots of phos-Thr 254, phos-Ser 311 and phos-Ser 536, in vehicle, GlcN or PUGNAc6TNF-a treated RASMCs. Blots were reprobed with
antibody against total p65 and b-actin. B: Representative Western blots of phos-Ser 536 in vehicle, GlcN or PUGNAc6TNF-a treated RASMCs. Blots
were reprobed with antibody against b-actin. Data, expressed as mean6SEM, are phos-p65/b-actin ratios as shown in the bar graphs. n=3–6/group.
*p,0.05 vs. vehicle treated RASMCs; # p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0024021.g005
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NFkB p65 in RASMCs. Quiescent cells were pretreated with GlcN (5 mM), PUGNAc (10
24 M) or vehicle for 1 hr, followed by TNF-a (10 ng/mL) for
an additional 10 min (A) or 1 hr (B, C, D). A, B: Left: Representative Western blots of total IkBa in vehicle, GlcN or PUGNAc6TNF-a treated RASMCs.
Blots were reprobed with antibody against b-actin. Right: The band intensity was measured and the ratio of IkBa to the corresponding total NFkB p65
was calculated. C. Left: Representative Western blots of phos-p65-Ser 536 in nuclear extracts of vehicle, GlcN or PUGNAc6TNF-a treated cells. Blots
were reprobed with antibody against total NFkB p65 and histone deacetylase (HDAC)-1 (as loading control). Right: The band intensity was measured
and the ratio of phos-p65-Ser 536 to the corresponding total NFkB p65 was calculated. D. Left: NFkB p65 immunoprecipitates (IP) obtained from
cellular extracts were analyzed by Western blot for IkBa and NFkB p65 (as input control). Right: The band intensity was measured and the ratio of
IkBa to the corresponding NFkB p65 was calculated. Data were expressed as means6SEM. n=3 or 6/group; *p,0.05 vs. vehicle treated RASMCs;
# p,0.05 vs. TNF-a-treated RASMCs.
doi:10.1371/journal.pone.0024021.g006
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e24021Real-time quantitative RT-PCR analyses of inflammatory
mediators
Real-time quantitative RT-PCR analysis was performed as
previously described [2,5,6]. Total RNA was extracted from cells
using TRIzol (Invitrogen, Carlsbad, CA), and treated with
DNAase I to remove genomic DNA. The protein- and DNA-
free RNA was reverse transcribed to cDNA and analyzed using the
SYBR Green RT-PCR kit (Applied Biosystems, Foster City, CA)
and specific primers for inflammatory mediators as described
before [2,5,6]. cDNA was amplified by PCR in the iCycler for 40
cycles and relative RNA levels were calculated using the iCycler
software and a standard equation (Applied Biosystems, Foster
City, CA). Unknowns were normalized to 18S rRNA and then
standardized to the mRNA level of vehicle treated RASMCs.
NFkB DNA binding activity
Nuclear protein was isolated from RASMCs using the Nuclear
and Cytoplasmic Extraction reagents (NE-PER) kit (Pierce). NFkB
DNA binding activity in nuclei was determined using the
TransAM NFkB p65 transcription factor assay kit according to
the manufacturer’s instructions (Active Motif, Carlsbad, CA) [33].
NFkB luciferase reporter assay
RASMCs were transiently co-transfected with pNFkB-Luc, a
luciferase reporter plasmid driven by NFkB response elements
(Panomics), and pRL-TK, a thymidine kinase promoter-Renilla
luciferase reporter plasmid (as a control for transfection efficiency)
using Lipofectamine Plus Transfection Reagent (Invitrogen).
Luciferase activities were measured by using the Dual Luciferase
Assay System (Promega, Madison, WI) with a luminometer and
normalized to protein concentration.
Western Blot Analyses
O-GlcNAc, IkBa,N F kB p65 and phosphorylated NFkB p65 (p-
p65) in RASMCs were determined by Western blot analysis using
anti- O-GlcNAc antibody CTD110.6, anti-IkBa (Santa Cruz),
NFkB p65 (Abcam), and phos-p65 antibodies (Cell Signaling) [5].
Protein loading was assessed by stripping the membranes and
reprobing with anti-b-actin antibody or histone deacetylase
(HDAC)-1 (Sigma).
Co-immunoprecipitation (Co-IP) analysis
RASMCs were lysed in Co-IP buffer (120 mM NaCl, 20 mM
Tris, pH 7.5, 2 mM EDTA, 1% Triton-X100, 1 mM sodium
vanadate, 10% glycerol) containing 0.5 mM PMSF and 20 mg/ml
apotinin, and then centrifuged at 12,000 g for 15 min at 4uC.
Protein concentration was determined by a Bradford-based
method (Bio-Rad). Following cell lysis, 600 mg of total protein
per sample were precleaned with normal rat/mouse IgG and
proteinA/G-plus beads (Santa Cruz) and then immunoprecipitat-
ed with anti- O-GlcNAc (Clone 18B10.C7, Millipore) or anti-
NFkB p65 antibody (Abcam), respectively, at 4uC for overnight.
The bound proteins on proteinA/G-plus beads were washed using
Co-IP buffer, centrifuged, eluted with 2X sample loading buffer,
boiled at 95uC for 5 min and stored at 280uC. Each Co-IP
experiment was repeated at least three times.
Statistical Analysis
Data are expressed as mean6SEM. Statistical analysis was
performed with one-way ANOVA or Student’s t test, as
appropriate. Values of P,0.05 were considered significant.
Supporting Information
Figure S1 Specificity of our anti-NFkB p65. O-GlcNAc IP
obtained from cellular extracts was analyzed by Western blot with
anti-p65 antibody pre-incubated with blocking peptide and no
signal was detected (left). The blot was then reprobed with anti-
NFkB p65 antibody and intense 65KD bands were detected
(right).
(TIF)
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